One year treatment with exenatide improves β cell function and glycaemic control in metformin treated type 2 diabetes patients

被引：0
|
作者：
Bunck, M. C.
Diamant, M.
Corner, A.
Eliasson, B.
Malloy, J. L.
Shaginian, R. M.
Deng, W.
Kendall, D. M.
Taskinen, M.-R.
Smith, U.
Yki-Jarvinen, H.
Heine, R. J.
机构：
[1] Vrije Univ Amsterdam, Dept Endocrinol, Med Ctr, Amsterdam, Netherlands
[2] Helsinki Univ Hosp, Dept Med, Helsinki, Finland
[3] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden
[4] Amylin Pharmaceut Inc, San Diego, CA USA
[5] Eli Lilly & Co, Houten, Netherlands
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0251
引用
收藏
页码：S111 / S112
页数：2
相关论文
共 50 条
  • [21] Effect of alogliptin combined with pioglitazone on glycaemic control in metformin-treated patients with type 2 diabetes
    DeFronzo, R.
    Burant, C.
    Fleck, P.
    Wilson, C.
    Mekki, Q.
    Pratley, R.
    DIABETOLOGIA, 2009, 52 : S295 - S295
  • [22] One Year Exenatide Therapy, Compared with Insulin Glargine, Reduces Postprandial Oxidative Stress in Metformin-Treated Patients with Type 2 Diabetes
    Bunck, Mathijs C.
    Corner, Anja
    Eliasson, Bjorn
    Wu, Yan
    Shaginian, Rimma M.
    Yan, Ping
    Heine, Robert J.
    Smith, Ulf
    Yki-Jaervinen, Hannele
    Taskinen, Marja-Riitta
    Diamant, Michaela
    DIABETES, 2009, 58 : A147 - A147
  • [23] β-cell function and glycemic control following one year exenatide therapy, and after 12 week wash out, in patients with type 2 diabetes
    Bunck, Mathijs C.
    Diamant, Michaela
    Corner, Anja
    Eliasson, Bjorn
    Malloy, Jaret L.
    Shaginian, Rimma M.
    Ding, Wei
    Kendall, David M.
    Taskinen, Marja-Ritta
    Smith, Ulf
    Yki-Jarvinen, Hannele
    Heine, Robert J.
    DIABETES, 2008, 57 : A32 - A32
  • [24] Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial
    van Raalte, Daniel H.
    Bunck, Mathijs C.
    Smits, Mark M.
    Hoekstra, T.
    Corner, Anja
    Diamant, Michaela
    Eliasson, Bjorn
    Marja-RiittaTaskinen
    Heine, Robert J.
    Smith, Ulf
    Yki-Jarvinen, Hannele
    Mari, Andrea
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 175 (04) : 345 - 352
  • [25] One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
    Buysschaert, M.
    Preumont, V.
    Oriot, P. R.
    Paris, I.
    Ponchon, M.
    Scarniere, D.
    Selvais, P.
    DIABETES & METABOLISM, 2010, 36 (05) : 381 - 388
  • [26] Pioglitazone, but not gliclazide or metformin, improves the adipokine profile of overweight type 2 diabetes patients independent of glycaemic control
    Reid, J.
    Lawrence, J. M.
    Taylor, G. J.
    Stirling, C. A.
    Reckless, J. P. D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 330 - 330
  • [27] Oral treatment improves glycaemic control in people with type 2 diabetes
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2017, 78 (11) : 609 - 609
  • [28] A NETWORK META ANALYSIS TO COMPARE GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH EXENATIDE ONCE WEEKLY OR LIRAGLUTIDE
    Scott, D.
    Boye, K. S.
    Timlin, L.
    Best, J. H.
    Clark, J.
    VALUE IN HEALTH, 2011, 14 (07) : A472 - A473
  • [29] Saxagliptin improves glycaemic control either as add-on therapy to metformin or as initial combination therapy with metformin in patients with type 2 diabetes
    Pfuetzner, A.
    Gurieva, I
    Antsiferov, M.
    Allen, E.
    Ravichandran, S.
    Chen, R.
    SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 168S - 169S
  • [30] Saxagliptin improves glycaemic control either as add-on therapy to metformin or as initial combination therapy with metformin in patients with type 2 diabetes
    Gurieva, I.
    Pfuetzner, A.
    Antsiferov, M.
    Allen, E.
    Ravichandran, S.
    Chen, R.
    EUROPEAN HEART JOURNAL, 2009, 30 : 226 - 227
12345